The page notes that sustainability has become a key focus alongside progress, speed, and efficiency in technology as climate change and energy costs rise.
The page highlights the growing importance of cybersecurity for businesses, from global enterprises to small local companies, due to reliance on digital systems.
Episteme Prognostics has filed a notice for an exempt securities offering to raise **$6.017 million** in new funding. The filing with the U.S. Securities and Exchange Commission (SEC) follows federal securities law requirements for unregistered offerings under **Rule 504 or 506 of Regulation D**. The company plans to proceed with the capital raise without a full public registration process.
Oct 2026intelligence360 - The Intelligent News SourceNews article
Episteme Prognostics, a startup spun out of Dartmouth, has created a **microarray test** that analyzes **chromatin accessibility** to predict how pancreatic cancer patients will respond to chemotherapy. The test leverages epigenetic data to tailor treatment decisions for individual patients, addressing the aggressive nature of pancreatic cancer. The company focuses on applying precision medicine through epigenetic insights.
